A clinical observation of the therapy for malignant hydrothorax by intra-thoracic injection using IL-2 combining with cisplatin

详细信息    查看全文

• 作者：Cheng Xu (1)
  Zaijun Zhang (1)
  Yuezhen Hu (1)
  Yeyuan Wang (1)
  Mingquan Li (1)
  
• 关键词：interleukin ; 2 (IL ; 2) ; Cisplatin ; biochemistry therapy ; malignant hydrothorax
• 刊名：The Chinese-German Journal of Clinical Oncology
• 出版年：2011
• 出版时间：January 2011
• 年：2011
• 卷：10
• 期：1
• 页码：24-26
• 全文大小：195KB
• 参考文献：1. Xie CM. Prevalence of pleural disease. Chin J Tuberc Respir Dis (Chinese), 2002, 24: 12.
  2. Zhang DM, Xie QL, Zhu WZ. Closed chest tube drainage fine cisplatin injection, erythromycin treatment of malignant pleural effusion ob-1. 2. served. Chin J Clin Oncol Rehabilit (Chinese), 2006, 3: 56-7.
  3. Xie MY, Jin LH, Pan SS, / et al. Built-in chest tube drainage of malignant pleural effusion treatment. J Clin Pulm Med (Chinese), 2007, 11: 104.
  4. Sheng LM. Double-lumen central venous catheter in the pleural puncture drainage. Hebei J Integr Tradit West (Chinese), 2006, 7: 933-34.
  5. Tu XW. Central venous catheter in the evaluation of the treatment of malignant pleural effusion. J Clin Pulm Med (Chinese), 2007, 12: 46-7.
  6. Wu DL. Dual path cisplatin treatment of malignant pleural and peritoneal effusions of 55 cases. J Clin Intern Med (Chinese), 2003, 20: 651.
  7. Qian J, Qin SK, Yang LQ, / et al. Carboplatin injection in treatment of 42 patients with malignant pleural effusion. Chin Oncol (Chinese), 2006, 16: 323.
  8. Zhuang XW, Yang YX, Zhang SQ, / et al. Bleomycin clinical analysis of malignant pleural effusion. Clin Cancer Res (Chinese), 2004, 16: 343-44.
  9. Lin PC, Chen N, Liu XY. Recombinant human interleukin -2 treatment of malignant pleural effusion. Mod Oncol (Chinese), 2005, 13: 823.
  10. Jia XL, Jiang Qm, Dong S, / et al. Recombinant human interleukin ? 42 cases of malignant pleural effusion clinical observation. Chin Clin Oncol (Chinese), 2006, 11: 469-70.
  11. Yang XF. Carboplatin and interleukin -2 treatment of malignant pleural effusion. Med Mag Chin (Chinese), 2005, 11: 654-55.
  12. He SX, Zhao XE, Li ZM. Chest tube interferon in combination with cisplatin in the treatment of malignant pleural effusion. Chin Med Her (Chinese), 2009, 6: 59-0.
  13. Wilkins HE 3rd, Connolly MM, Grays P, / et al. Recombinant interferon alpha-2b in the management of malignant pleural effusions. Chest, 1997, 111: 1597-599. CrossRef
  14. Zhang HN. Intrapleural injection of TNF treatment of malignant pleural effusion. Chin Clin New Med (Chinese), 2004, 4: 907-08.
  15. Liu HM, Li LH, Wang MC. Aidi injection combined with cisplatin in the treatment of malignant pleural effusion of lung cancer clinical observation of 42 cases. J Pract Med Tech (Chinese), 2006, 13: 3260.
  16. Zhang HX, Chen FA, Zhao X. KLT combined with cisplatin for malignant pleural effusion efficacy. Chin Med Factory (Chinese), 2004, 17: 495-96.
  17. Xie JL, Mo FL, Yan ZQ. The treatment of malignant pleural effusion Research. Clin J Med Offic (Chinese), 2007, 35: 112-14.
  
• 作者单位：Cheng Xu (1)
  Zaijun Zhang (1)
  Yuezhen Hu (1)
  Yeyuan Wang (1)
  Mingquan Li (1)
  
  1. Department of Cancer, Guangyuan Central Hospital, Guangyuan, 628000, China
  

文摘

Objective The aim of our study was to explore the short-term effects and complication of interleukin-2 (IL-2) combining with Cisplatin in the treatment of malignant hydrothorax. Methods Sixty-two cases patients with malignant hydrothorax were randomly divided into two groups. Observation group was 31 examples, thoracic cavity injection IL-2 and Cisplatin; 31 cases in control group using Cisplatin alone intra-thoracic injection. The regime of every week for 1- weeks was used to observe short term effects and complications. Results The total response rate in observe group was higher than that in control group (90.3% vs. 68.1%), which had statistically significant difference (P < 0.05). The complications included gastrointestinal tract reaction, bone marrow inhibition, chest pain and fever. The incidence rates of chest pain and fever in observe group was slightly higher than that in control group, but there was no statistically significant difference (P > 0.05). Conclusion The IL-2 combining with Cisplatin intra-thoracic injection for malignant hydrothorax has the features of good therapeutic effects and slight poisonous side effects, which is worth to be used in clinic.